Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.02
MSLI's Cash to Debt is ranked lower than
97% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.55 vs. MSLI: 0.02 )
Ranked among companies with meaningful Cash to Debt only.
MSLI' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 7.09 Max: No Debt
Current: 0.02
Equity to Asset 0.53
MSLI's Equity to Asset is ranked lower than
66% of the 719 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. MSLI: 0.53 )
Ranked among companies with meaningful Equity to Asset only.
MSLI' s Equity to Asset Range Over the Past 10 Years
Min: 0.2  Med: 0.54 Max: 0.92
Current: 0.53
0.2
0.92
Interest Coverage 0.06
MSLI's Interest Coverage is ranked lower than
100% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 101.94 vs. MSLI: 0.06 )
Ranked among companies with meaningful Interest Coverage only.
MSLI' s Interest Coverage Range Over the Past 10 Years
Min: 0.05  Med: 1.09 Max: 23.79
Current: 0.06
0.05
23.79
F-Score: 3
Z-Score: 0.27
M-Score: -1.98
WACC vs ROIC
15.27%
-1.15%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 0.38
MSLI's Operating margin (%) is ranked lower than
72% of the 732 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.61 vs. MSLI: 0.38 )
Ranked among companies with meaningful Operating margin (%) only.
MSLI' s Operating margin (%) Range Over the Past 10 Years
Min: -1112.12  Med: -15.67 Max: 19.4
Current: 0.38
-1112.12
19.4
Net-margin (%) -10.39
MSLI's Net-margin (%) is ranked lower than
78% of the 733 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.95 vs. MSLI: -10.39 )
Ranked among companies with meaningful Net-margin (%) only.
MSLI' s Net-margin (%) Range Over the Past 10 Years
Min: -1787.71  Med: -30.83 Max: 17.19
Current: -10.39
-1787.71
17.19
ROE (%) -4.94
MSLI's ROE (%) is ranked lower than
74% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. MSLI: -4.94 )
Ranked among companies with meaningful ROE (%) only.
MSLI' s ROE (%) Range Over the Past 10 Years
Min: -90.89  Med: -16.19 Max: 5.02
Current: -4.94
-90.89
5.02
ROA (%) -2.86
MSLI's ROA (%) is ranked lower than
72% of the 787 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. MSLI: -2.86 )
Ranked among companies with meaningful ROA (%) only.
MSLI' s ROA (%) Range Over the Past 10 Years
Min: -49.48  Med: -12.42 Max: 4.57
Current: -2.86
-49.48
4.57
ROC (Joel Greenblatt) (%) -10.43
MSLI's ROC (Joel Greenblatt) (%) is ranked lower than
74% of the 777 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.38 vs. MSLI: -10.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MSLI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -627.84  Med: -115.82 Max: 92.73
Current: -10.43
-627.84
92.73
Revenue Growth (3Y)(%) -1.40
MSLI's Revenue Growth (3Y)(%) is ranked lower than
70% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. MSLI: -1.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MSLI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -1.4 Max: 85.1
Current: -1.4
0
85.1
EBITDA Growth (3Y)(%) -12.10
MSLI's EBITDA Growth (3Y)(%) is ranked lower than
82% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. MSLI: -12.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MSLI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -21.8  Med: 9.3 Max: 62.2
Current: -12.1
-21.8
62.2
EPS Growth (3Y)(%) 21.60
MSLI's EPS Growth (3Y)(%) is ranked higher than
71% of the 530 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. MSLI: 21.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MSLI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -85.1  Med: -2.9 Max: 138.1
Current: 21.6
-85.1
138.1
GuruFocus has detected 3 Warning Signs with Merus Labs International Inc $MSLI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MSLI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

MSLI Guru Trades in

MSLI Guru Trades in

MSLI Guru Trades in

Q2 2015

MSLI Guru Trades in Q2 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MSLI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 3741
Compare:NAS:NEOS, NAS:CPIX, NAS:BPTH, NAS:CPRX, NAS:SPHS, OTCPK:ZOMHF, OTCPK:OWCP, NAS:SMMT, NAS:TYHT, NAS:SCYX, NAS:CPHR, NAS:ADMP, NAS:AGRX, NAS:PSDV, NAS:LPCN, NAS:SNDX, NAS:EPIX, NAS:MEIP, NAS:JNP, OTCPK:MRPHF » details
Traded in other countries:MSL.Canada, 9ML.Germany,
Merus Labs International Inc is a specialty pharmaceutical company. The Company acquires and licenses novel pharmaceutical products.

Merus Labs International Inc was incorporated on October 1, 2012 in British Columbia. The Company is a specialty pharmaceutical company. It acquires prescription medicines in various categories which include on patent but at maturity stage of product life cycle; branded generics; under promoted products; Niche market pharmaceuticals; and products with annual sales below critical threshold for large pharma. The Company competes with multinational pharmaceutical development corporations to small, single product companies that may limit their activities to a particular therapeutic area or region or territory.

Ratios

vs
industry
vs
history
Price/Owner Earnings (ttm) 7.84
MSLI's Price/Owner Earnings (ttm) is ranked higher than
92% of the 289 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.32 vs. MSLI: 7.84 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MSLI' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 1.12  Med: 10.31 Max: 188.33
Current: 7.84
1.12
188.33
P/B 0.62
MSLI's P/B is ranked higher than
95% of the 751 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. MSLI: 0.62 )
Ranked among companies with meaningful P/B only.
MSLI' s P/B Range Over the Past 10 Years
Min: 0.29  Med: 0.78 Max: 2.63
Current: 0.62
0.29
2.63
P/S 1.27
MSLI's P/S is ranked higher than
76% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. MSLI: 1.27 )
Ranked among companies with meaningful P/S only.
MSLI' s P/S Range Over the Past 10 Years
Min: 0.82  Med: 2.9 Max: 53.85
Current: 1.27
0.82
53.85
PFCF 5.36
MSLI's PFCF is ranked higher than
94% of the 202 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.11 vs. MSLI: 5.36 )
Ranked among companies with meaningful PFCF only.
MSLI' s PFCF Range Over the Past 10 Years
Min: 1.28  Med: 6.48 Max: 70.56
Current: 5.36
1.28
70.56
POCF 5.15
MSLI's POCF is ranked higher than
89% of the 269 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. MSLI: 5.15 )
Ranked among companies with meaningful POCF only.
MSLI' s POCF Range Over the Past 10 Years
Min: 1.26  Med: 5.64 Max: 97.22
Current: 5.15
1.26
97.22
EV-to-EBIT -148.19
MSLI's EV-to-EBIT is ranked lower than
99.99% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.32 vs. MSLI: -148.19 )
Ranked among companies with meaningful EV-to-EBIT only.
MSLI' s EV-to-EBIT Range Over the Past 10 Years
Min: -199.9  Med: -0.6 Max: 143.2
Current: -148.19
-199.9
143.2
EV-to-EBITDA 7.62
MSLI's EV-to-EBITDA is ranked higher than
86% of the 562 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.15 vs. MSLI: 7.62 )
Ranked among companies with meaningful EV-to-EBITDA only.
MSLI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -155.7  Med: 1.1 Max: 20.6
Current: 7.62
-155.7
20.6
Current Ratio 0.77
MSLI's Current Ratio is ranked lower than
93% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.34 vs. MSLI: 0.77 )
Ranked among companies with meaningful Current Ratio only.
MSLI' s Current Ratio Range Over the Past 10 Years
Min: 0.38  Med: 1.36 Max: 14.42
Current: 0.77
0.38
14.42
Quick Ratio 0.55
MSLI's Quick Ratio is ranked lower than
93% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. MSLI: 0.55 )
Ranked among companies with meaningful Quick Ratio only.
MSLI' s Quick Ratio Range Over the Past 10 Years
Min: 0.31  Med: 1.36 Max: 14.42
Current: 0.55
0.31
14.42
Days Inventory 111.16
MSLI's Days Inventory is ranked higher than
52% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.25 vs. MSLI: 111.16 )
Ranked among companies with meaningful Days Inventory only.
MSLI' s Days Inventory Range Over the Past 10 Years
Min: 118.87  Med: 227.84 Max: 458.88
Current: 111.16
118.87
458.88
Days Sales Outstanding 109.54
MSLI's Days Sales Outstanding is ranked lower than
74% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.25 vs. MSLI: 109.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
MSLI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.61  Med: 109.54 Max: 1249.47
Current: 109.54
3.61
1249.47

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -45.00
MSLI's 3-Year Average Share Buyback Ratio is ranked lower than
92% of the 429 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. MSLI: -45.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MSLI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -116.3  Med: -28.3 Max: 25.8
Current: -45
-116.3
25.8

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.52
MSLI's Price/Projected FCF is ranked higher than
96% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.72 vs. MSLI: 0.52 )
Ranked among companies with meaningful Price/Projected FCF only.
MSLI' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.16  Med: 0.81 Max: 2.82
Current: 0.52
0.16
2.82
Price/Median PS Value 0.44
MSLI's Price/Median PS Value is ranked higher than
93% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. MSLI: 0.44 )
Ranked among companies with meaningful Price/Median PS Value only.
MSLI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.03  Med: 0.81 Max: 6.91
Current: 0.44
0.03
6.91
Earnings Yield (Greenblatt) (%) -0.70
MSLI's Earnings Yield (Greenblatt) (%) is ranked lower than
73% of the 760 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. MSLI: -0.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MSLI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.7  Med: 56.8 Max: 5232.3
Current: -0.7
0.7
5232.3

More Statistics

Revenue (TTM) (Mil) $69.14
EPS (TTM) $ -0.06
Beta2.45
Short Percentage of Float0.04%
52-Week Range $0.70 - 1.90
Shares Outstanding (Mil)117.00

Analyst Estimate

Sep17 Sep18 Sep19
Revenue (Mil $) 90 90 93
EPS ($) -0.04 0.01 0.08
EPS w/o NRI ($) -0.04 0.01 0.08
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for MSLI

Headlines

Articles On GuruFocus.com
Slow Growth Ahead; Updates on Merus Labs International, Enghouse Systems, Athabasca Minerals Oct 05 2015 
Update on Merus Labs International, Athabasca Minerals Inc, Enghouse Systems Limited, WiLAN Inc. Jun 22 2015 
Merus Labs International: A Pharma Stock With Growth Potential Mar 30 2015 

More From Other Websites
What Makes Merus Labs (MSLI) a Strong Sell? Jan 09 2017
MERUS LABS INTERNATIONAL INC. Financials Jan 06 2017
Blog Coverage Ionis Pharma Records Three Milestones Payment Within a Week Dec 23 2016
Merus Labs International, Inc. :MSLI-US: Earnings Analysis: 2016 By the Numbers : December 21, 2016 Dec 21 2016
Merus Labs Reports Fiscal Q4 and 2016 Results Dec 14 2016
Merus Labs Reports Fiscal Q4 and 2016 Results Dec 14 2016
Merus Labs Announces Date of Fiscal 2016 Earnings Release Dec 12 2016
Merus Labs Announces Date of Fiscal 2016 Earnings Release Dec 12 2016
Merus Labs Receives NASDAQ Notice Regarding Minimum Bid Price Requirements Nov 18 2016
Merus Receives Nasdaq Notice Regarding Minimum Bid Price Requirements Nov 16 2016
Merus Receives Nasdaq Notice Regarding Minimum Bid Price Requirements Nov 16 2016
Barry Fishman Joins Aurora Board as Independent Director Oct 12 2016
Merus Labs Announces Reduced Interest Rate on Senior Secured Debt and Reduced Leverage Oct 03 2016
Merus Labs Announces Reduced Interest Rate on Senior Secured Debt and Reduced Leverage Oct 03 2016
Merus Labs Reports Fiscal Q3 2016 Results Aug 30 2016
What Falling Estimates & Price Mean for Merus Labs International (MSLI) Aug 22 2016
Merus Labs Reports Fiscal Q3 2016 Results Aug 15 2016
Merus Labs Reports Fiscal Q3 2016 Results Aug 15 2016
Merus Labs to Present at U.S. Investor Conference and Announces Date of Fiscal Q3 2016 Earnings... Aug 10 2016
Merus Labs to Present at U.S. Investor Conference and Announces Date of Fiscal Q3 2016 Earnings... Aug 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)